9 terminated. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 1 | 2 | Terminated 2 |
Follow entinostat: new trials by email Literature Review of entinostat trials Research Report on entinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma Entinostat, Nivolumab, Ipilimumab - Renal Cell Carcinoma | Phase 2 | Terminated | Roberto Pili | 12 | 2018-07-31 | 2024-09-03 |
| Entinostat Neuroendocrine (NE) Tumor Entinostat - Neuroendocrine Tumors | Phase 2 | Terminated | Antonio Fojo | 5 | 2017-12-13 | 2026-03-02 |
| Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Atezolizumab, Bevacizumab, Entinostat - Metastatic Cancer, Renal Cancer | Phase 1 / Phase 2 | Terminated | Roberto Pili | 31 | 2017-06-29 | 2025-03-20 |
| Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Azacitidine, Docetaxel, Entinostat - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 17 | 2013-05-01 | 2018-07-27 |
| Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia entinostat, imatinib mesylate, laboratory biomarker analysis - Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2010-10-01 | 2017-08-08 |
| Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery entinostat, anastrozole, diagnostic laboratory biomarker analysis - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Terminated | University of Maryland, Baltimore | 5 | 2010-10-01 | 2022-05-03 |
| Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery Azacitidine, Entinostat, Laboratory Biomarker Analysis - Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 13 | 2010-09-01 | 2019-02-05 |
| A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma Entinostat - Hodgkin's Lymphoma | Phase 2 | Terminated | Syndax Pharmaceuticals | 49 | 2009-04-13 | 2019-10-22 |
| A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib Entinostat, Erlotinib - Non Small Cell Lung Cancer | Phase 2 | Terminated | Syndax Pharmaceuticals | 8 | 2008-08-01 | 2023-07-06 |
Carcinoma, Non-Small-Cell Lung (3) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Hodgkin Disease (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neuroendocrine Tumors (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Triple Negative Breast Neoplasms (1)
National Cancer Institute (NCI) (3) · Roberto Pili (2) · Syndax Pharmaceuticals (2) · Antonio Fojo (1) · University of Maryland, Baltimore (1)
United States (9)
Alex Adjei, MD (1) · Antonio Fojo, MD, PhD (1) · Charles Rudin (1) · Julie Brahmer (1) · Nabil Adra, MD (1) · Patrick Brown (1) · Roberto Pili, MD (1) · Saranya Chumsri (1)
P30CA006973 (2), U01CA070095 (1)